Free Trial
NASDAQ:CRBU

Caribou Biosciences Q1 2024 Earnings Report

Caribou Biosciences logo
$1.63 -0.11 (-6.32%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.69 +0.06 (+3.74%)
As of 06:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Caribou Biosciences EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
$2.43 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$570.00 thousand
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Caribou Biosciences' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Caribou Biosciences Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
CRBU Caribou Biosciences, Inc. - Seeking Alpha
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company focused on developing transformative therapies based on its proprietary CRISPR technology. The company’s platform is built around novel CRISPR-Cas enzymes and delivery systems designed to enable precise gene editing in both cell‐based and in vivo applications. Caribou’s core therapeutic areas include oncology, immunology and rare genetic diseases, where its technologies aim to create next-generation cell therapies and targeted gene-editing treatments.

Among Caribou’s leading programs is its allogeneic cell therapy platform, which employs engineered T cells to target blood cancers and solid tumors. The company has also advanced multiple in vivo gene-editing candidates, leveraging lipid nanoparticle and viral delivery technologies to correct disease-causing mutations directly within patients. In addition to therapeutic development, Caribou provides its CRISPR tools and enzyme variants to a broad network of academic and industry collaborators working in human health research, agricultural biotechnology and synthetic biology.

Founded in 2011, Caribou Biosciences traces its origins to the University of California, Berkeley, where Nobel laureate Jennifer Doudna and her colleagues pioneered CRISPR research. Since its inception, the company has grown from an academic spin-out into a publicly traded entity, establishing state-of-the-art research facilities in the San Francisco Bay Area and collaborating with partners worldwide. Caribou’s strategic alliances encompass pharmaceutical collaborations, licensing agreements and joint development projects across North America, Europe and Asia.

Leadership at Caribou includes a seasoned management team with deep expertise in biotechnology, drug development and regulatory affairs. Co-founder and chief scientific officer Jennifer Doudna continues to guide the company’s scientific direction, while the executive team brings experience from leading global biopharma organizations. Together, they oversee a multidisciplinary workforce committed to advancing Caribou’s pipeline of CRISPR-based therapies and expanding the capabilities of gene-editing platforms on a global scale.

View Caribou Biosciences Profile

More Earnings Resources from MarketBeat